Protein predicts Gleevec resistance in gastrointestinal tumors
Friday, May 16, 2008 - 10:07
in Health & Medicine
Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors (GISTs) could indicate that the patient would be less responsive to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia.